The Conversation (0)
- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Trending
Trending Articles
Trending Press Releases
Trending Companies
Purpose Bitcoin ETF
BTCC:CA
Silver47 Exploration
AGA:CC
Syntheia
SYAI:CC
CI Galaxy Bitcoin ETF
BTCX.B:CA
Trending Reports
Resource
Popular Lists
Investing Ideas
Outlook Reports
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
Investing Guides
Tech
Popular Lists
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
Investing Ideas
Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
Investing Guides
Life Science
Popular Lists
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Investing Guides
Genmab (Nasdaq:GEN) announced that worldwide net sales of DARZALEX (daratumumab) as reported by Johnson & Johnson were USD 1,242 million in 2017. As quoted in the press release: Net sales were USD 884 million in the U.S. and net sales in the rest of the world were USD 358 million. Genmab receives royalties on the …
Genmab (Nasdaq:GEN) announced that worldwide net sales of DARZALEX (daratumumab) as reported by Johnson & Johnson were USD 1,242 million in 2017.
As quoted in the press release:
Net sales were USD 884 million in the U.S. and net sales in the rest of the world were USD 358 million. Genmab receives royalties on the worldwide net sales of DARZALEX under the exclusive worldwide license to Janssen Biotech, Inc. to develop, manufacture and commercialize DARZALEX.
DARZALEX was approved in the U.S. in November 2015, in Europe in May 2016 and in Japan in September 2017. Worldwide net sales of DARZALEX in 2016 were USD 572 million, resulting in royalty income of DKK 458 million to Genmab.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.